Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Prostatic Neoplasms 7Recurrence 6Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Lymphoma 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Glioblastoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Mouth Neoplasms 2Leukemia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hyperthermia 2

Interventions

Haloperidol 2Lorazepam 1Chlorpromazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × Delirium × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
110 enrolled

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡